Development and evaluation of a genomic signature for the prediction and mechanistic assessment of nongenotoxic hepatocarcinogens in the rat

Toxicological Sciences

Volumn 124, Issue 1, 2011, Pages 54-74

  Fielden, Mark R ^a   Adai, Alex ^b   Dunn, Robert T ^a   Olaharski, Andrew ^c   Searfoss, George ^d   Sina, Joe ^e   Aubrecht, Jiri ^f   Boitier, Eric ^g   Nioi, Paul ^a,e   Auerbach, Scott ^h   Jacobson kram, David ⁱ   Raghavan, Nandini ^j   Yang, Yi ^k   Kincaid, Andrew ^b   Sherlock, Jon ^l   Chen, Shen Jue ^m   Car, Bruce ^m  

^a AMGEN INC   (United States)

^b ASURAGEN INC   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

^f PFIZER INC   (United States)

^g SANOFI   (France)

^h NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

ⁱ CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^j JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^k ABBOTT LABORATORIES   (United States)

^l Life Technologies Corporation   (United States)

^m BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

Biomarkers; Carcinogenesis; In vitro and alternatives; Liver; Methods; Nongenotoxic; Predictive toxicology; Safety evaluation; Systems toxicology; Toxicogenomics

Indexed keywords

BIOLOGICAL MARKER; CARCINOGEN;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; GENETIC ANALYSIS; LIVER CARCINOGENESIS; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREDICTION; PROGNOSIS; QUANTITATIVE ANALYSIS; RAT; SAFETY; SENSITIVITY AND SPECIFICITY; STANDARDIZATION;

ANIMALS; CARCINOGENS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; GENOMICS; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MODELS, GENETIC; PREDICTIVE VALUE OF TESTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84155187516     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr202     Document Type: Article

References (45)

1. Allen, D. G., Pearse, G., Haseman, J. K., and Maronpot, R. R. (2004). Prediction of rodent carcinogenesis: an evaluation of prechronic liver lesions as forecasters of liver tumors in NTP carcinogenicity studies. Toxicol. Pathol. 32, 393-401.
2. Auerbach, S. S., Shah, R. R., Mav, D., Smith, C. S., Walker, N. J., Vallant, M. K., Boorman, G. A., and Irwin, R. D. (2010). Predicting the hepatocarcinogenic potential of alkenylbenzene flavoring agents using toxicogenomics and machine learning. Toxicol. Appl. Pharmacol. 243, 300-314.
3. Bercu, J. P., Jolly, R. A., Flagella, K. M., Baker, T. K., Romero, P., and Stevens, J. L. (2010). Toxicogenomics and cancer risk assessment: a framework for key event analysis and dose-response assessment for nongenotoxic carcinogens. Regul. Toxicol. Pharmacol. 58, 369-381.
4. Booth, E.. D., Jones, E., and Elliott, B., M. (2007). Review of the in vitro and in vivo genotoxicity of dichlorvos. Regul. Toxicol. Pharmacol. 49, 316-326.
5. Brambilla, G., and Martelli, A. (2009). Update on genotoxicity and carcinogenicity testing of 472 marketed pharmaceuticals. Mutat. Res. 681, 209-229.
6. Chen, H. H., Chen, T. W., and Lin, H. (2010). Pravastatin attenuates carboplatin-induced nephrotoxicity in rodents via peroxisome proliferatoractivated receptor alpha-regulated heme oxygenase-1. Mol. Pharmacol 78, 36-45.
7. Christensen, F. M., Eisenreich, S. J., Rasmussen, K., Sintes, J. R., Sokull-Kluettgen, B., and Van de Plassche, E. J. (2011). European experience in chemicals management: integrating science into policy. Environ. Sci. Technol. 45, 80-89.
8. Cohen, S. M. (2004). Human carcinogenic risk evaluation: an alternative approach to the two-year rodent bioassay. Toxicol. Sci. 80, 225-259.
9. Cohen, S. M. (2010). Evaluation of possible carcinogenic risk to humans based on liver tumors in rodent assays: the two-year bioassay is no longer necessary. Toxicol. Pathol. 38, 487-501.
10. Contrera, J. F., Matthews, E. J., and Daniel Benz, R. (2003). Predicting the carcinogenic potential of pharmaceuticals in rodents using molecular structural similarity and E-state indices. Regul. Toxicol. Pharmacol. 38, 243-259.
11. Davies, T. S., and Monro, A. (1995). Marketed human pharmaceuticals reported to be tumorigenic in rodents. J. Amer. Coll. Toxicol. 14, 90-107.
12. DiMartino, J. F., Selleri, L., Traver, D., Firpo, M. T., Rhee, J., Warnke, R., O'Gorman, S., Weissman, I. L., and Cleary, M. L. (2001). The Hox cofactor and proto-oncogene Pbx1 is required for maintenance of definitive hematopoiesis in the fetal liver. Blood 98, 618-626.
13. Elcombe, C. R., Odum, J., Foster, J. R., Stone, S., Hasmall, S., Soames, A. R., Kimber, I., and Ashby, J. (2002). Prediction of rodent nongenotoxic carcinogenesis: evaluation of biochemical and tissue changes in rodents following exposure to nine nongenotoxic NTP carcinogens. Environ. Health Perspect. 110, 363-375.
14. Ellinger-Ziegelbauer, H., Gmuender, H., Bandenburg, A., and Ahr, H. J. (2008). Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies. Mutat. Res. 637, 23-39.
15. Ellinger-Ziegelbauer, H., Stuart, B., Wahle, B., Bomann, W., and Ahr, H. J. (2004). Characteristic expression profiles induced by genotoxic carcinogens in rat liver. Toxicol. Sci. 77, 19-34.
16. Fielden, M. R., Brennan, R., and Gollub, J. (2007). A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol. Sci. 99, 90-100.
17. Fielden, M. R., Nie, A., McMillian, M., Elangbam, C. S., Trela, B. A., Yang, Y., Dunn, R. T., II., Dragan, Y., Fransson-Stehen, R., Bogdanffy, M., et al. (2008). Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat. Toxicol. Sci. 103, 28-34.
18. Gold, L. S., Manley, N. B., Slone, T. H., Rohrbach, L., and Garfinkel, G. B. (2005). Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature through 1997 and by the National Toxicology Program in 1997-1998. Toxicol. Sci. 85, 747-808.
19. Haseman, J. K., Huff, J. E., Zeiger, E., and McConnell, E. E. (1987). Comparative results of 327 chemical carcinogenicity studies. Environ. Health Perspect. 74, 229-235.
20. Ito, N., Tamano, S., and Shirai, T. (2003). A medium-term rat liver bioassay for rapid in vivo detection of carcinogenic potential of chemicals. Cancer Sci. 94, 3-8.
21. Jacobs, A. (2005). Prediction of 2-year carcinogenicity study results for pharmaceutical products: how are we doing? Toxicol. Sci. 88, 18-23.
22. Jacobs, A., and Jacobson-Kram, D. (2004). Human carcinogenic risk evaluation, part III: assessing cancer hazard and risk in human drug development. Toxicol. Sci. 81, 260-262.
23. Kirkland, D., Aardema, M., Henderson, L., and Muller, L. (2005). Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat. Res. 584, 1-256.
24. Kitchin, K. T., Brown, J. L., and Kulkarni, A. P. (1993). Predicting rodent carcinogenicity of halogenated hydrocarbons by in vivo biochemical parameters. Teratog. Carcinog. Mutagen. 13, 167-184.
25. Kitchin, K. T., Brown, J. L., and Kulkarni, A. P. (1994). Complementarity of genotoxic and nongenotoxic predictors of rodent carcinogenicity. Teratog. Carcinog. Mutagen. 14, 83-100.
26. Lee, Y., Buchanan, B. G., Mattison, D. M., Klopman, G., and Rosenkranz, H. S. (1995). Learning rules to predict rodent carcinogenicity of nongenotoxic chemicals. Mutat. Res. 328, 127-149.
27. Maronpot, R. R., Flake, G., and Huff, J. (2004). Relevance of animal carcinogenesis findings to human cancer predictions and prevention. Toxicol. Pathol. 32(Suppl. 1), 40-48.
28. Mauthe, R. J., Gibson, D. P., Bunch, R. T., and Custer, L. (2001). The syrian hamster embryo (SHE) cell transformation assay: review of the methods and results. Toxicol. Pathol. 29(Suppl.), 138-146.
29. Melnick, R. L., Thayer, K. A., and Bucher, J. R. (2008). Conflicting views on chemical carcinogenesis arising from the design and evaluation of rodent carcinogenicity studies. Environ. Health Perspect. 116, 130-135.
30. Michel, C., Roberts, R. A., Desdouets, C., Isaacs, K. R., and Boitier, E. (2005). Characterization of an acute molecular marker of nongenotoxic rodent hepatocarcinogenesis by gene expression profiling in a long term clofibric acid study. Chem. Res. Toxicol. 18, 611-618.
31. Montero, R., and Ostrosky, P. (1997). Genotoxic activity of praziquantel. Mutat Res 387, 123-139.
32. Nie, A. Y., McMillian, M., Parker, J. B., Leone, A., Bryant, S., Yieh, L., Bittner, A., Nelson, J., Carmen, A., Wan, J., et al. (2006). Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol. Carcinog. 45, 914-933.
33. Nioi, P., Pardo, I.. D., Sherratt, P.. J., Fielden, M.. R., Gollub, J., Nie, A., and Snyder, R. D. (2008). Prediction of non-genotoxic carcinogenesis in rats using changes in gene expression following acute dosing. Chem. Biol. Interact. 176, 252-260.
34. Tatematsu, M., Tsuda, H., Shirai, T., Masui, T., and Ito, N. (1987). Placental glutathione S-transferase (GST-P) as a new marker for hepatocarcinogenesis: in vivo short-term screening for hepatocarcinogens. Toxicol. Pathol. 15, 60-68.
35. Thomas, R. S., Allen, B. C., Nong, A., Yang, L., Bermudez, E., Clewell, H. J., III., and Andersen, M. E. (2007). A method to integrate benchmark dose estimates with genomic data to assess the functional effects of chemical exposure. Toxicol. Sci. 98, 240-248.
36. Thomas, R. S., Bao, W., Chu, T. M., Bessarabova, M., Nikolskaya, T., Nikolsky, Y., Andersen, M. E., and Wolfinger, R. D. (2009). Use of shortterm transcriptional profiles to assess the long-term cancer-related safety of environmental and industrial chemicals. Toxicol. Sci 112, 311-321.
37. Thomas, R. S., Clewell, H. J., III., Allen, B. C., Wesselkamper, S. C., Wang, N. C., Lambert, J. C., Hess-Wilson, J. K., Zhao, Q. J., and Andersen, M. E. (2010). Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. Toxicol. Sci. 120, 194-205.
38. Uehara, T., Hirode, M., Ono, A., Kiyosawa, N., Omura, K., Shimizu, T., Mizukawa, Y., Miyagishima, T., Nagao, T., and Urushidani, T. (2008). A toxicogenomics approach for early assessment of potential nongenotoxic hepatocarcinogenicity of chemicals in rats. Toxicology 250, 15-26.
39. Vanparys, P., Corvi, R., Aardema, M., Gribaldo, L., Hayashi, M., Hoffmann, S., and Schechtman, L. (2011). ECVAM prevalidation of three cell transformation assays. ALTEX 28, 56-59.
40. Waites, C. R., Dominick, M. A., Sanderson, T. P., and Schilling, B. E. (2007). Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist. Toxicol. Sci. 100, 248-258.
41. Ward, J. M. (2008). Value of rodent carcinogenesis bioassays. Toxicol. Appl. Pharmacol. 226, 212.
42. Waters, M. D., Jackson, M., and Lea, I. (2010). Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods. Mutat. Res. 705, 184-200.
43. Whysner, J., and Williams, G. M. (1996a). D-limonene mechanistic data and risk assessment: absolute species-specific cytotoxicity, enhanced cell proliferation, and tumor promotion. Pharmacol. Ther. 71, 127-136.
44. Whysner, J., and Williams, G. M. (1996b). Saccharin mechanistic data and risk assessment: urine composition, enhanced cell proliferation, and tumor promotion. Pharmacol. Ther. 71, 225-252.
45. Yamasaki, H., Ashby, J., Bignami, M., Jongen, W., Linnainmaa, K., Newbold, R. F., Nguyen-Ba, G., Parodi, S., Rivedal, E., Schiffmann, D., et al. (1996). Nongenotoxic carcinogens: development of detection methods based on mechanisms: a European project. Mutat. Res. 353, 47-63.